Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07015190 · ClinicalTrials.gov registry record · Phase 3
Neoadjuvant Darovasertib in Primary Uveal Melanoma
A Phase 3 study of Uveal Melanoma, sponsored by IDEAYA Biosciences.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 520
- Enrollment target
- 20
- Study locations
NCT07015190: Recruiting Phase 3 study of Uveal Melanoma, sponsored by IDEAYA Biosciences.
NCT07015190 is a Phase 3 study of Uveal Melanoma that is actively recruiting participants, run by IDEAYA Biosciences. The registered enrollment target is 520 participants, above the 127-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (309% higher). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07015190, a Phase 3 study of Uveal Melanoma, is actively recruiting participants, sponsored by IDEAYA Biosciences.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 520 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
Primary Outcome
Loss of Best Corrected Visual Acuity (BCVA) of ≥ 15 letters using Early Treatment Diabetic Retinopathy Study (ETDRS) BCVA
Conditions Studied
Interventions
- DRUG Darovasertib
- PROCEDURE Primary Local Therapy
Study Locations (20)
California
- UCSD Moores Cancer Center - La Jolla
- Jules Stein Eye Institute - Los Angeles
- University of California Irvine Medical Center - Orange
- Stanford Comprehensive Cancer Center - Palo Alto
- Kaiser Permanente-Riverside Medical Center - Riverside
New York
- Herbert Irving Comprehensive Cancer Center - New York
- Memorial Sloan Kettering Cancer Center - 1275 York Ave - New York
- Northwell Health Cancer Institute - New York
Colorado
- University of Colorado Hospital - Aurora
- The Melanoma and Skin Cancer Institute - Englewood
Florida
- Mayo Clinic Jacksonville - Jacksonville
- USF Health Eye Institute - Tampa
Michigan
- W Kellogg Eye Center - Ann Arbor
- The Cancer and Hematology Centers of West Michigan (CHCWM) - Grand Rapids
Arizona
- Mayo Clinic Scottsdale - PPDS - Scottsdale
Maryland
- Wilmer Eye Institute - Baltimore
Massachusetts
- Massachusetts General Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 520 participants |
| Start Date | 2026-01-25 |
| Est. Completion | 2031-03 |
| Phase | Phase 3 |
What NCT07015190 shows while recruiting
NCT07015190 is an interventional study that assigns participants to a tested intervention. The registered 520 participants enrollment target is mid-sized for trials with a published cap, above the 127-participant average among 29 other Uveal Melanoma trials with a reported enrollment target (309% higher).
The record links to 1 condition, with Uveal Melanoma appearing as the primary indexed condition, and to 2 interventions - of which Darovasertib is the first listed.
NCT07015190 names 20 study sites across 11 states, led by California, New York, Colorado.
Frequently Asked Questions
What is clinical trial NCT07015190 about?
NCT07015190 is a clinical study titled "Neoadjuvant Darovasertib in Primary Uveal Melanoma". This is a Phase 3, randomized, multi-center, open-label study of neoadjuvant darovasertib in subjects with primary non-metastatic uveal melanoma (OptimUM-10)
What is the current status of trial NCT07015190?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 520 participants. The study started on 2026-01-25. Estimated completion is 2031-03.
What conditions does trial NCT07015190 study?
This clinical trial studies the following conditions: Uveal Melanoma.
What interventions are being tested in trial NCT07015190?
The interventions under investigation include: Darovasertib (DRUG), Primary Local Therapy (PROCEDURE).
Who is sponsoring clinical trial NCT07015190?
This trial is sponsored by IDEAYA Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07015190 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Uveal Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07015190's enrollment target sits among peer trials
520 2nd of 29 the highest of 29 other Uveal Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Uveal Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
RECRUITING · Phase 3
-
Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Metastatic Uveal Melanoma (SUMIT)
COMPLETED · Phase 3
-
Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver
RECRUITING · NA
-
A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
RECRUITING · Phase 2
-
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
RECRUITING · Phase 2
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323581 · 520 participants · NA
Endovascular Treatment of TAAA and Aortic Arch Aneurysms Using Fenestrated and Branched Stent Grafts
- NCT04656496 · 520 participants · NA
NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors
- NCT05445778 · 520 participants · Phase 3
Mirvetuximab Soravtansine With Bevacizumab Versus Bevacizumab as Maintenance in Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer
- NCT05498428 · 520 participants · Phase 2
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI